---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-26-000126"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2026-09-18T12:23:28+00:00"
generated_at: "2026-09-18T12:25:10.039061+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Halozyme prices $1.3B convertible senior notes due 2033 at 1.50%; upsized from $1.05B

## Summary
- $1.3B aggregate principal of 1.50% convertible notes due Oct 1, 2033, upsized from $1.05B; 13-day greenshoe for up to $200M.
- Initial conversion price ~$139.84/share (27.5% premium above $109.68 close); cap price of capped calls ~$208.39/share.
- Net proceeds ~$1.275B; ~$162.5M funds capped calls, remainder for note repurchases, working capital, acquisitions.
- To repurchase ~$151.7M of 0.25% 2027 notes (cost ~$217.0M) and $220.0M of 1.00% 2028 notes (cost ~$435.5M).
- Closing expected Sept 22, 2026; offering private to QIBs under Rule 144A; settle conversions in cash plus shares if applicable.

## SEC filing metadata
- accession: 0001159036-26-000126
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2026-09-18T12:23:28+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000126/0001159036-26-000126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000126/halo-20260917.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-26-000126
- JSON: https://secwatch.observer/filing/0001159036-26-000126.json
- Plain text: https://secwatch.observer/filing/0001159036-26-000126.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.